Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business UpdatesGlobeNewsWire • 08/06/20
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease PatientsGlobeNewsWire • 08/05/20
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020GlobeNewsWire • 08/04/20
Anavex Is Likely To Report Positive Parkinson's Disease Trial Results For A2-73, Increasing Share ValueSeeking Alpha • 07/07/20
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)GlobeNewsWire • 07/06/20
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeGlobeNewsWire • 07/01/20
Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to BuyZacks Investment Research • 06/26/20
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialGlobeNewsWire • 06/16/20
Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 06/15/20
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseGlobeNewsWire • 06/04/20
Has Anavex Life Sciences (AVXL) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/02/20
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)GlobeNewsWire • 05/21/20
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s DiseaseGlobeNewsWire • 04/23/20
Anavex Life Sciences (AVXL) Stock Moves -0.38%: What You Should KnowZacks Investment Research • 04/03/20
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Strong BuyZacks Investment Research • 02/17/20
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/07/20
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett SyndromeGlobeNewsWire • 02/03/20